Home

CANCER BLOOD TESTS

Protein and Artificial Intelligence Solutions to Cancer Blood Testing and Early Detection

OTraces has developed patent-pending cancer blood test technology that observes fluctuations in immune response via cytokine activity in the tumor microenvironment (TME) to detect solid tumors starting at Stage 0. This is 7-9 months earlier than ctDNA liquid biopsy and known competition and offers both higher accuracy and substantially lower costs.

OTraces is seeking investors and business partners to speed commercialization in global markets and to further validate the technology for numerous cancer applications.

OTraces has developed, filed U.S. and international patents on, and is preparing to start launching a math-, physics- and artificial intelligence-based cancer blood test technology that can:

    • Boost the accuracy of cancer and other disease blood tests to typically 90%+ on a challenging predictive power basis — well in excess of current industry levels.
    • Detect and measure cytokine activity in the tumor micro-environment (TME) and thereby achieve real time diagnosis of tumor status and immune response in vitro without biopsy — a human diagnostic first.
    • Detect early stage cancers (stage 0 and 1) with superior sensitivity to Methylated ctDNA methods, 95%+ versus less the 30% {see Technology Web Page).

 

OTraces applies AI based computational techniques from physics to human biological testing which has never been done before. This technology has been clinically validated in blinded trials for both breast and prostate cancer at leading institutions.

These methods are embedded in cloud-based software, that is ready to be deployed and utilized by to collaborators, business partners and research groups worldwide, and can be used on instruments and lab procedures already in common use across the globe. Moreover, it is compatible with high volume LDT and screening applications to facilitate and speed commercialization, especially for lab developed tests usually not requiring local regulatory approval to launch.

The following video demonstrates this technology and outlines its potential.

Contacts:

Company/Investor Inquiries:
Keith Lingenfelter; Founder and CEO of OTraces, Inc.
phone: +01-301-529-3824 cell/txt
email: keith.lingenfelter@otraces.com

Contact-Media Inquiries:
Nancy Rose Senich
phone: +01-202-262-6996 cell/txt
email: nancy@rose4results.com